🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Moderna delays shipment of about 600,000 COVID-19 vaccine doses to Canada

Published 2021-03-25, 11:28 p/m
© Reuters
AZN
-
PFE
-
AZN
-
MRNA
-

March 25 (Reuters) - Moderna Inc MRNA.O has delayed the shipment of 590,400 doses of its COVID-19 vaccine that were due to arrive in Canada this weekend, the federal procurement minister said on Thursday.

Moderna informed Canadian officials that the delay was due to a "backlog in its quality assurance process", Anita Anand said, adding that the company assured the remaining doses will be shipped no later than Thursday next week.

Canada was set to receive 846,000 doses from Moderna this week, of which 255,600 were delivered on Wednesday, a government source told Reuters.

"Once Moderna's final quality assurance process has been completed, the doses will be released for shipment."

Anand said the U.S. drugmaker gave assurance that the issue was a "minor hiccup" and it would not impact the shipment of 855,600 doses set for the week of April 5.

Canada has received 5.9 million vaccine doses so far, and expects to get 3.2 million next week, including from Pfizer Inc (NYSE:PFE) PFE.N , AstraZeneca (NASDAQ:AZN) Plc AZN.L from the United States and the rescheduled Moderna shipment.

The country is facing a potential third wave of infections as the more transmissible B.1.1.7 virus variant first discovered in the UK drives outbreaks in some hot spots. has 38,922 active cases at present and reported 5,202 new cases, as of March 25. (https://

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.